Prosecution Insights
Last updated: August 15, 2026

Revance Therapeutics Inc.

4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready

Portfolio Summary

4
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
2
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only2 (50%)
Multi-statute (no §101)2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SWIFT, CANDICE LEE 2 57.4% +36.7%
OGUNBIYI, OLUWATOSIN A 1 63.7% +41.5%
JACKSON-TONGUE, LAKIA J 1 68.8% +20.8%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18278169 METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY SWIFT, CANDICE LEE 47d
17912513 INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES SWIFT, CANDICE LEE

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18414311 Albumin-Free Botulinum Toxin Formulations OGUNBIYI, OLUWATOSIN A 26d
18278169 METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY SWIFT, CANDICE LEE 47d
17951220 INJECTABLE BOTULINUM TOXIN FORMULATIONS JACKSON-TONGUE, LAKIA J
17912513 INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES SWIFT, CANDICE LEE

Top Art Units

Art UnitApps
1645 2
1657 2

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18414311 Albumin-Free Botulinum Toxin Formulations OGUNBIYI, OLUWATOSIN A 1645 §102 Non-Final OA 26d Pending Jan 16, 2024
18278169 METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY SWIFT, CANDICE LEE 1657 §103§112Other Final Rejection 47d Pending Aug 21, 2023
17951220 INJECTABLE BOTULINUM TOXIN FORMULATIONS JACKSON-TONGUE, LAKIA J 1645 §102 Final Rejection Pending Sep 23, 2022
17912513 INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES SWIFT, CANDICE LEE 1657 §103§112Other Non-Final OA Pending Sep 18, 2022

Managing Revance Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month